Exploiting metabolic vulnerabilities through synergistic ferroptosis and disulfidptosis for breast cancer therapy
This study successfully developed a novel therapeutic strategy that combines ferroptosis and disulfidptosis using FCSP@876 MOFs, offering a promising approach for overcoming ferroptosis resistance in breast cancer therapy.
Authors
- Ziting Xu (ORCID: https://orcid.org/0009-0005-7974-4620)
- Yingjia Li (ORCID: https://orcid.org/0000-0002-8885-2317)
- Bingxia Zhao (ORCID: https://orcid.org/0000-0003-1095-5719)
- Yang Gao (ORCID: https://orcid.org/0000-0002-2875-618X)
- Minyi Liu (ORCID: https://orcid.org/0000-0003-3959-1891)
- Li Zhang (ORCID: https://orcid.org/0000-0002-3265-5699)
- Yu Liang (ORCID: https://orcid.org/0000-0002-6823-620X)
- Qiuyu Li (ORCID: https://orcid.org/0000-0002-6330-9932)
- Hekui Lan
- Mengdan Gao
Institutions
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1016/j.jare.2025.03.052
- Citations
- 13
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 19.74